MASITINIB HAS UNIQUE AND COMPETITIVE POSITIONING IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS DUE TO ITS DISTINCTIVE SAFETY AND EFFICACY PROFILE AND MECANISM OF ACTIONS TARGETING BOTH MICROGLIA AND MAST ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果当前正在显示可能无法访问的结果。
隐藏无法访问的结果